Key points from article :
A recent research by Institute For Hormonal Balance studied the effects of senolytic drugs (DQ and DQF) on ageing markers in humans.
DQ treatment (Dasatinib and Quercetin) increased markers of epigenetic ageing (DNA methylation and age acceleration) in most measures after 3 and 6 months.
Interestingly, adding Fisetin (DQF) to the treatment seemed to lessen the increase in epigenetic age acceleration compared to DQ alone.
The study also observed changes in immune cell populations between the two groups, potentially explaining the different effects on ageing markers.
This research was conducted as a Phase I pilot study in humans, requiring further investigation to confirm and understand the long-term effects.
This was a small-scale study requiring further investigation to confirm and understand long-term effects.
The study's participants, averaging around 60 with some in their 40s, might have been too young to show significant effects due to potentially lower levels of targeted cells.
Additionally, current methods for measuring epigenetic age might be insensitive to how senescent cells affect human ageing.
The study was published in the journal Aging Cell with collaborators from TruDiagnostic, Buck Institute and Cornell University.
